A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma
Genmab
Genmab
AstraZeneca
Merck Sharp & Dohme LLC
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
ImmunityBio, Inc.
Hoffmann-La Roche
Celgene
AstraZeneca
Guangzhou Lupeng Pharmaceutical Company LTD.
AstraZeneca
Janssen Research & Development, LLC
Hutchmed
Janssen Pharmaceutical K.K.
ADC Therapeutics S.A.
BeiGene
Merck Sharp & Dohme LLC
Debiopharm International SA
Ipsen
Hoffmann-La Roche
TerSera Therapeutics LLC
Celgene
MEI Pharma, Inc.
Innovent Biologics (Suzhou) Co. Ltd.
Spectrum Pharmaceuticals, Inc
SecuraBio
Eli Lilly and Company
Eli Lilly and Company
Celgene
Boehringer Ingelheim
Hoffmann-La Roche
Seagen Inc.
Gilead Sciences
Pharmacyclics LLC.
Seagen Inc.
Hoffmann-La Roche
Gilead Sciences
Gilead Sciences
Seagen Inc.
Hoffmann-La Roche
MedImmune LLC
Pfizer
Hoffmann-La Roche
Hoffmann-La Roche
Hoffmann-La Roche
Hoffmann-La Roche
Genentech, Inc.
MedImmune LLC
Takeda
Seagen Inc.
US Oncology Research